Compare Stocks: ANIK, ANVS, SVRA, and CRVS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIK Anika Therapeutics	$20.81	$19.46	$8.67 ▼ $22.88	$278.44M	0.2	81,873 shs	118,466 shs
ANVS Annovis Bio	$1.15 +1.2%	$1.64	$1.04 ▼ $5.50	$48.65M	1.24	1.26 million shs	677,303 shs
CRVS Corvus Pharmaceuticals	$12.56	$14.00	$5.74 ▼ $26.95	$1.06B	0.87	1.02 million shs	4.46 million shs
SVRA Savara	$5.37	$5.49	$3.34 ▼ $7.01	$1.10B	0.25	1.30 million shs	2.18 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIK Anika Therapeutics	0.00%	-0.24%	-4.45%	+46.55%	+133.82%
ANVS Annovis Bio	0.00%	+2.58%	-36.24%	-33.79%	-50.47%
CRVS Corvus Pharmaceuticals	0.00%	-2.71%	-13.14%	0.00%	+113.97%
SVRA Savara	0.00%	+1.32%	-3.94%	-5.62%	+52.12%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIK Anika Therapeutics	$20.81	$19.46	$8.67 ▼ $22.88	$278.44M	0.2	81,873 shs	118,466 shs
ANVS Annovis Bio	$1.15 +1.2%	$1.64	$1.04 ▼ $5.50	$48.65M	1.24	1.26 million shs	677,303 shs
CRVS Corvus Pharmaceuticals	$12.56	$14.00	$5.74 ▼ $26.95	$1.06B	0.87	1.02 million shs	4.46 million shs
SVRA Savara	$5.37	$5.49	$3.34 ▼ $7.01	$1.10B	0.25	1.30 million shs	2.18 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIK Anika Therapeutics	0.00%	-0.24%	-4.45%	+46.55%	+133.82%
ANVS Annovis Bio	0.00%	+2.58%	-36.24%	-33.79%	-50.47%
CRVS Corvus Pharmaceuticals	0.00%	-2.71%	-13.14%	0.00%	+113.97%
SVRA Savara	0.00%	+1.32%	-3.94%	-5.62%	+52.12%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIK Anika Therapeutics	2.75	Moderate Buy	$22.00	5.72% Upside
ANVS Annovis Bio	2.25	Hold	$12.00	939.86% Upside
CRVS Corvus Pharmaceuticals	2.88	Moderate Buy	$33.33	165.39% Upside
SVRA Savara	2.88	Moderate Buy	$10.00	86.22% Upside

Current Analyst Ratings Breakdown

Latest ANIK, ANVS, SVRA, and CRVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/18/2026	ANIK Anika Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$21.00 ➝ $23.00
9/16/2026	CRVS Corvus Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/27/2026	ANVS Annovis Bio	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$8.00 ➝ $7.00
8/18/2026	ANVS Annovis Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/5/2026	ANIK Anika Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/30/2026	ANIK Anika Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$18.00 ➝ $21.00
7/30/2026	ANIK Anika Therapeutics	Barrington Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$21.00
7/30/2026	CRVS Corvus Pharmaceuticals	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/28/2026	CRVS Corvus Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	SVRA Savara	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/10/2026	CRVS Corvus Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIK Anika Therapeutics	$112.82M	2.47	N/A	N/A	$9.95 per share	2.09
ANVS Annovis Bio	N/A	N/A	N/A	N/A	$0.64 per share	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	$0.13 per share	99.09	$0.73 per share	N/A
SVRA Savara	N/A	N/A	N/A	N/A	$1.00 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIK Anika Therapeutics	-$10.88M	-$0.27	N/A	71.76	14.86	-3.14%	0.20%	0.15%	11/4/2026 (Estimated)
ANVS Annovis Bio	-$28.85M	-$1.79	N/A	N/A	N/A	N/A	-685.98%	-258.77%	11/11/2026 (Estimated)
CRVS Corvus Pharmaceuticals	-$15.28M	-$0.61	N/A	N/A	N/A	N/A	-36.15%	-33.62%	11/3/2026 (Estimated)
SVRA Savara	-$118.84M	-$0.58	N/A	N/A	N/A	N/A	-90.28%	-68.95%	11/11/2026 (Estimated)

Latest ANIK, ANVS, SVRA, and CRVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	ANVS Annovis Bio	-$0.4533	-$0.40	+$0.0533	-$0.40	N/A	N/A
8/11/2026	Q2 2026	SVRA Savara	-$0.1413	-$0.16	-$0.0188	-$0.16	$2.00 million	N/A
8/6/2026	Q2 2026	CRVS Corvus Pharmaceuticals	-$0.1591	-$0.19	-$0.0309	-$0.19	N/A	N/A
7/29/2026	Q2 2026	ANIK Anika Therapeutics	$0.03	$0.42	+$0.39	$0.24	$29.21 million	$32.61 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIK Anika Therapeutics	N/A	N/A	N/A	N/A	N/A
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SVRA Savara	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIK Anika Therapeutics	N/A	4.48	3.19
ANVS Annovis Bio	N/A	3.47	3.47
CRVS Corvus Pharmaceuticals	N/A	16.16	16.16
SVRA Savara	0.21	10.13	10.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIK Anika Therapeutics	91.53%
ANVS Annovis Bio	15.83%
CRVS Corvus Pharmaceuticals	46.64%
SVRA Savara	87.93%

Insider Ownership

Company	Insider Ownership
ANIK Anika Therapeutics	12.08%
ANVS Annovis Bio	15.92%
CRVS Corvus Pharmaceuticals	19.70%
SVRA Savara	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIK Anika Therapeutics	235	13.38 million	11.77 million	Optionable
ANVS Annovis Bio	7	42.68 million	35.89 million	Optionable
CRVS Corvus Pharmaceuticals	37	84.12 million	67.55 million	Optionable
SVRA Savara	70	205.46 million	194.57 million	Optionable

ANIK, ANVS, SVRA, and CRVS Headlines

Recent News About These Companies

Savara Inc. (NASDAQ:SVRA) Given Consensus Rating of "Moderate Buy" by Analysts

September 18 at 4:13 AM | marketbeat.com

Bank of New York Mellon Corp Acquires New Shares in Savara Inc. $SVRA

September 8, 2026 | marketbeat.com

Jupiter Topco LLC Invests $2.88 Million in Savara Inc. $SVRA

September 3, 2026 | marketbeat.com

BlackRock Inc. Takes $76.97 Million Position in Savara Inc. $SVRA

August 31, 2026 | marketbeat.com

6,976,810 Shares in Savara Inc. $SVRA Purchased by Nantahala Capital Management LLC

August 29, 2026 | marketbeat.com

Algert Global LLC Purchases 464,645 Shares of Savara Inc. $SVRA

August 27, 2026 | marketbeat.com

ADAR1 Capital Management LLC Purchases New Shares in Savara Inc. $SVRA

August 26, 2026 | marketbeat.com

Spruce Street Capital LP Acquires New Shares in Savara Inc. $SVRA

August 25, 2026 | marketbeat.com

Deutsche Bank AG Makes New $5.33 Million Investment in Savara Inc. $SVRA

August 25, 2026 | marketbeat.com

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis ...

August 24, 2026 | uk.finance.yahoo.com

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026

August 24, 2026 | businesswire.com

Savara Inc. (NASDAQ:SVRA) Receives Average Rating of "Moderate Buy" from Analysts

August 24, 2026 | marketbeat.com

Savara Inc. (SVRA) Latest Press Releases & Corporate News - Yahoo Finance

August 20, 2026 | finance.yahoo.com

Savara Reports Second Quarter 2026 Financial Results and Provides Business Update

August 11, 2026 | caledonianrecord.comC

Savara: High Potential Binary Bet Cruising To PDUFA After 3 Month Speed Bump

August 5, 2026 | seekingalpha.com

Savara (SVRA) Gets a Buy from Piper Sandler

July 24, 2026 | theglobeandmail.com

Here's Why You Should Add Savara Stock to Your Portfolio Now

July 22, 2026 | zacks.com

What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline

June 27, 2026 | fool.com

What Is Driving Attention Toward Savara’s Rare Disease Strategy?

June 15, 2026 | kalkinemedia.comK

Savara Announces New Employment Inducement Grant

June 12, 2026 | businesswire.com

Savara Announces Chief Financial and Administrative Officer Transition

June 8, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIK, ANVS, SVRA, and CRVS Company Descriptions

Anika Therapeutics NASDAQ:ANIK

$20.81 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$20.81 0.00 (0.00%)

As of 05:55 AM Eastern

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

Annovis Bio NYSE:ANVS

$1.15 +0.01 (+1.23%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$1.16 +0.01 (+0.43%)

As of 05:25 AM Eastern

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Corvus Pharmaceuticals NASDAQ:CRVS

$12.56 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$12.50 -0.07 (-0.52%)

As of 04:02 AM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Savara NASDAQ:SVRA

$5.37 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$5.46 +0.09 (+1.64%)

As of 06:41 AM Eastern

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANIK, ANVS, SVRA, and CRVS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANIK, ANVS, SVRA, and CRVS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANIK, ANVS, SVRA, and CRVS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIK, ANVS, SVRA, and CRVS Company Descriptions

Anika Therapeutics NASDAQ:ANIK

Annovis Bio NYSE:ANVS

Corvus Pharmaceuticals NASDAQ:CRVS

Savara NASDAQ:SVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANIK, ANVS, SVRA, and CRVS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANIK, ANVS, SVRA, and CRVS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANIK, ANVS, SVRA, and CRVS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIK, ANVS, SVRA, and CRVS Company Descriptions

Anika Therapeutics NASDAQ:ANIK

Annovis Bio NYSE:ANVS

Corvus Pharmaceuticals NASDAQ:CRVS

Savara NASDAQ:SVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools